

To,
The Board of Directors
Artemis Medicare Services Limited
Plot No. 14 Sector 20
Dwarka, New Delhi-110075

Sub: Report on Reconciliation of Share Capital Audit of the Company for the quarter ended December 31, 2020.

We have examined the soft copy of Register of Members, beneficiary details furnished by the Depositories and other records maintained by **M/s. Artemis Medicare Services limited** (hereinafter referred to as 'the Company') and its Registrar and Share Transfer Agent for Electronic Connectivity, **M/s. Alankit Assignments Limited**, for giving report in accordance with the Circular No. D&CC/FITTC/CIR-16/2002 December 31, 2002 issued by the Securities and Exchange Board of India and Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 (as amended).

In our opinion and to the best of our knowledge and according to the information and explanations given to us and based on such verification as considered necessary, we hereby submit our report for the quarter ended **December 31, 2020** of the Company.

1.	For Quarter Ended	31.12.2020	
2.	ISIN	INE025R01013	
3.	Face Value	Rs. 10/- per share	
4.	Name of the Company	Artemis Medicare Services Limited	
5.	Registered Office Address	Plot No. 14 Sector 20, Dwarka, New Delhi-110075	
6.	Correspondence Address	Artemis Hospital, Sector-51, Gurugram-122001(Haryana)	
7.	Telephone & Fax. Nos.	Tel: 91-124-4807-180	
8.	Email Address	investor@artemishospitals.com	
9.	Names of the Stock Exchanges where the company's securities are listed	1. National Stock Exchange of India Limited (NSE) 2. BSE Limited (BSE)	
		No. of Shares	% of Total Issued Capital
10.	Issued Capital	1,32,37,700	100
11.	Listed Capital (NSE & BSE) (as per company records)	1,32,06,240	99.76
12.	Held in dematerialized Form in	9,39,996	7.10



	CDSL																			
13.	Held in dematerialized Form in NSDL	1,21,21,371	91.57																	
14.	Physical	1,76,333	1.33																	
15.	Total No. of Shares (12+13+14)	1,32,37,700	100																	
16.	Reasons for difference between (10 & 11) (11 & 15) & Reasons for difference between (10 & 15)	BSE and NSE vide its letters dated January 21, 2020 has accorded their approval for listing and trading of 1,32,06,240 equity shares Company and 31,460 Equity shares which are allotted in physical form are held in abeyance. N.A.																		
17.	Certifying the details of Changes in share capital during the quarter under consideration as per table below:																			
	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 15%;">Particulars*</th> <th style="width: 10%;">No. of Shares</th> <th style="width: 15%;">Applied/Not Applied for listing</th> <th style="width: 15%;">Listed on Stock Exchanges (Specify Names)</th> <th style="width: 10%;">Whether intimated to CDSL</th> <th style="width: 10%;">Whether intimated to NSDL</th> <th style="width: 15%;">In-prin. Appr. Pending for SE (Specify Names)</th> </tr> </thead> <tbody> <tr> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody> </table>						Particulars*	No. of Shares	Applied/Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)	-	-	-	-	-	-	-
Particulars*	No. of Shares	Applied/Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)														
-	-	-	-	-	-	-														
	*Rights, bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buy Back, Capital Reduction Forfeiture, any other (to specify)																			
18.	Register of Members is updated (Yes/No) If not, updated upto which date	Yes																		
19.	Reference of previous quarter with regard to excess dematerialized Shares, if any	Nil																		
20.	Has the company resolved the matter mentioned in point No. 19 above in the current quarter? If not, reason why?	NA																		
21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:																			
	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;">Total no. of demat requests</th> <th style="width: 15%;">No. of requests</th> <th style="width: 15%;">No. of shares</th> <th style="width: 40%;">Reasons for delay</th> </tr> </thead> <tbody> <tr> <td>Confirmed after 21 days</td> <td>Nil</td> <td>Nil</td> <td>Nil</td> </tr> <tr> <td>Pending for more than 21 days</td> <td>Nil</td> <td>Nil</td> <td>Nil</td> </tr> </tbody> </table>					Total no. of demat requests	No. of requests	No. of shares	Reasons for delay	Confirmed after 21 days	Nil	Nil	Nil	Pending for more than 21 days	Nil	Nil	Nil			
Total no. of demat requests	No. of requests	No. of shares	Reasons for delay																	
Confirmed after 21 days	Nil	Nil	Nil																	
Pending for more than 21 days	Nil	Nil	Nil																	



**DMK ASSOCIATES
COMPANY SECRETARIES**

22.	Name, Telephone & Fax no. of the Compliance Officer of the Company	Shilpa Budhia Company Secretary & Compliance Officer 91-124-4511-111
23.	Name, Address, Tel. & fax No., Reg. no. of Certifying Auditor	Deepak Kukreja DMK Associates Practicing Company Secretaries 31/36, Basement, Old Rajinder Nagar New Delhi-110060 C.P. No. 8265 Telefax: + 91-11-42432721
24.	Appointment of common agency for share Registry work <i>If yes, (name & address)</i>	YES Alankit Assignments Limited ALANKIT House 4E/2, Jhandewalan Extension, New Delhi – 110055 Phone.: + 91-11-4254 1234 & 2354 1234 Fax: : + 91-11-23552001 Email info@alankit.com Website: www.alankit.com
25.	Any other detail that the auditor may like to provide	NA

Place: New Delhi
Date: 13.01.2021



**FOR DMK ASSOCIATES
COMPANY SECRETARIES**

(DEEPAK KUKREJA)

Partner

C.P. No. 8265

FCS No. 4140

UDIN: F004140B001981500